UNSPSC 51341506: Fosamprenavir sodium

This classification denotes an enzyme inhibitor with the molecular formula C25H34N3O9PS.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XSG28FSA0W, chemically known as carbamic acid, ((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)-, c-((3s)-tetrahydro-3-furanyl) ester, disodium salt but more generally known as fosamprenavir sodium, which bears US NIH Compound Identifier 131537.

Most nations, for tariff and trade purposes, schedule fosamprenavir sodium under HS 29350090 and SITC 51580. As of Q4 2014, FOSAMPRENAVIR SODIUM remains US FDA's Preferred Term for this commodity. Fosamprenavir sodium bears US NLM identifiers UMLS ID C1366241 and NCI Concept Code C72786. SMILES: CC(C)CN(C[C@H]([C@H](CC1CCCCC1)NC(=O)O[C@H]2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3CCC(CC3)N.[NA+].[NA+].

UNSPSC 51341506 Fosamprenavir sodium, a Commodity code, shows minimal alignment between its nominal pharmaceutical scope and the recent state and local opportunities tagged to it. The recent solicitations posted under this code span emergency medical supplies for first responders, naloxone and drug deactivation systems for county health departments, direct-to-manufacturer pharmacy programs at the state level, and generic multi-source pharmaceuticals through cooperative purchasing — none of which centers on fosamprenavir sodium specifically. The tagged opportunities reflect broader procurement patterns in public health, emergency response, and pharmacy benefit management rather than a focused market for this particular antiretroviral medication. Issuing bodies include county health departments (Seminole County, Florida), city fire departments and municipal purchasing offices (City of Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to county health facilities; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies for the Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5 percent bid discount reserved for certified Small Local Business Enterprises; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with price competitiveness weighted at 75 percent and awards effective July 1, 2026; and the Texas HHS Request for Information HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The code itself does not appear to reflect genuine procurement demand for fosamprenavir sodium in state and local markets.